AMINO AND AMIDO DERIVATIVES OF CHLORO NITRO AMINO AND ALKYLAMINO PYRAZINES USEFUL AS ADJUNCTS TO RADIATION THERAPY

Abstract: 2-Substituted amino derivatives of 6-amino-3-chloro-5-­ nitropyrazin-2-yl are prepared by converting 3-amino-5,6-­ dichloropyrazinecarboxylic acid to 5,6-dichloro-3-­ nitropyrazinamine and treating said compound with an amine to produce the corresponding 2-substituted amino compound. 2,6-Di(alkylamino) derivatives of chloronitropyrazines are prepared from dichloronitropyrazinamine by diazotiza­ tion of the amine followed by halogen exchange to produce an intermediate dichloro-halo nitropyrazine followed by reaction with one or two moles of an alkyl amine to effect replacement of one or two of the pyrazine halogens. N-acyl derivatives of 6-(alkylamino)-5-chloro-3-nitro­ pyrazinamines are prepared by treatment of 5,6-dichloro-3-­ nitropyrazinamine with an acylating agent to produce the corresponding acylated pyrazinamine followed by treatment of said acylate dpyrazinamine with a lower alkylamine to replace one of the chloro substituents and produce a 2-acylamino-6-(alkylamino)-5-chloro-3-nitro pyrazinamine.

Description: TITLE OF THE INVENTION AMINO AND AMIDO DERIVATIVES OF CHLORO NITRO AMINO AND ALKYLAMINO PYRAZINES USEFUL AS ADJUNCTS TO RADIATION THERAPY BACKGROUND OF THE INVENTION This invention relates to substituted derivatives of 6-amino-3-chloro-5-nitropyrazinamino compounds and the acid addition salts thereof, used to selectively sensitize tumor cells to therapeutic radiation and thus increase the effective therapeutic ratio of radiologic treatment. This invention also relates to the process of preparing such compounds by first converting 3-amino-5,6-dichloropyrazine carboxylic acid by nitration in sulfuric/nitric acid to 5,6-dichloro-3-nitropyrazinamine and subsequently treating said 5,6-dichloro-compound in the presence of a base such as a tertiary amine to produce the desired 2-substituted compounds and if desired, converting said 2-substituted pyrazines to the acid addition salts thereof. This invention also relates to 2,6-disubstituted derivatives of chloronitropyrazines of the formula: EMI2.1 in which A is defined as an amino substituent wherein at least one of the hydrogens of the amino substituent is replaced by a lower alkyl, a hydroxy substituted lower alkyl, an alkoxy substituted lower alkyl radical. It also relates to the process of preparing such compounds starting with the corresponding 2-halo-5,6-dichloro-3-nitropyrazine by reaction with a selected alkyl amine or substituted alkylamine to replace the 2-halo and 6-chloro substituents. This invention also relates to N-acyl derivatives of 6- (alkylamino) -5-chloro-3- nitropyrazinamine used to sensitize tumor cells to therapeutic radiation and thus increase the effective therapeutic ratio of radiation treatment. It also relates to the process of preparing such compounds starting with 5,6-dichloro-3-nitropyrazinamine by first contacting said pyrazinamine with an acylating agent derived from a lower aliphatic carboxylic acid to afford the corresponding acylated pyrazinamine and further treating said acylated pyrazine with a lower (alkyl or substituted alkyl) amine compound to replace one of the chloro substituents and produce a 2-acylamino-6 (alkylamino) -5-chloro-3-nitropyrazine. In addition, the present invention relates to pharmaceutical compositions comprising such pyrazine compounds and to methods of treatment comprising administering such compounds to patients undergoing radiation therapy to enhance the effectiveness of such treatment. At the present time, certain other unrelated compounds are in experimental clinical use as radiation sensitizers. However, these compounds--for example, metronidazole and misonidazole--suffer from the drawback that they also cause symptoms of neurotoxicity which limits their usefulness. The compounds of the present invention are effective radiation sensitizers, but are believed to have a more favorable therapeutic ratio. DETAILED DESCRIPTION OF THE INVENTION One group of compounds of the present invention which are useful as radiation sensitizers are 2 substituted derivatives of 6-amino-3-chloro-5nitropyrazine and the acid addition salts thereof of the formula: EMI3.1 wherein R and R1 are each hydrogen, a saturated or unsaturated alkyl substituent of from 1-6 carbon atoms, substituted alkyl substituents in which one or more of the alkyl hydrogens is replaced by hydroxy, alkoxy, carboalkoxy, phenyl, pyrimidinyl, pyridyl or imidazolyl or when taken together along with the nitrogen atom to which they are attached represent a 6-membered heterocyclic ring including morpholine, piperazine and N-lower alkyl piperazine in combination with a pharmaceutical carrier. A preferred subgroup of novel compounds of the present invention are represented by the following structural formula: EMI4.1 wherein R2 and R3 are each individually hydrogen, lower alkyl groups substituted by hydroxy, halo including fluoro, chloro or bromo, or lower alkanoyl substituted by one or more hydroxy groups, provided that at least one of R2 and R3 is a substituent other than hydrogen and the corresponding acid addition salts formed by reaction of the above amino compound with an equimolar amount of a strong mineral acid such as hydrochloric acid, hydrobromic acid, sulfuric and phosphoric acids. The amines described above are prepared from the known 3-amino-5,6-dichloropyrazine carboxylic acid E. J. Cragoe, Jr., O. W. Woltersdorf, Jr., J. B. Bicking, S. F. Kwong, J. H. Jones, J. Med. Chem., 10, 66 (1967). The carboxylic acid is dissolved in sulfuric acid or fuming sulfuric acid. To the solution formed in this manner, a mixture of equal volumes of sulfuric and nitric acid or the corresponding fuming sulfuric and fuming nitric acids are added to the solution to effect replacement of the carboxylic acid substituent by a nitro-substituent. The nitric and sulfuric acids are used in approximately equimolar amounts to the carboxylic acid reagent. Preferably, however, these acids are used in from 10-100% molar excess. The reaction temperature is maintained between 0 and 500C for a period of 0.5 to 5.0 hours. The progress of the reaction is followed by observation of the evolution of carbon dioxide from the reaction mixture. This reaction is illustrated in the following reaction scheme: EMI5.1 The product is conveniently recovered from the reaction mixture by pouring the entire mixture onto ice whereupon the product is precipitated as a crude yellow solid. Further purification is effected by dissolving the crude product in a solvent such as ethyl acetate and washing with an alkaline solution such as aqueous sodium carbonate to remove traces of acid. The solution of product is then filtered to remove insoluble impurities and the product recovered from the filtrate by evaporation of solvent leaving substantially pure product as a solid residue. Compound II hereinabove is then treated with an amine compound to replace the chloro-substituent as illustrated hereinbelow: EMI6.1 The reaction of the dichloro-nitropyrazine II with the amine reagent is preferably carried out in a solvent for the reactant. The solvent employed is a lower alkanol such as methanol, ethanol, isopropanol; ethers such as tetrahydrofuran; dimethyl formamide; and acetonitrile. The amine reactant is preferably present in approximately a 5-10% molar excess over the nitropyrazine. The reagents are first mixed and then preferably heated to a temperature of 20-800C for a period of from 0.5 to 24 hours. In addition to the reagents and the solvent it is generally preferred to carry out the reaction in the presence of at least an equimolar amount of an organic base. Tertiary amines such as triethylamine and pyridine are preferred. The progress of the reaction is followed by the use of thin layer chromatography. As indicated hereinabove acid addition salts of compounds of Formula I may be prepared by mixing a selected compound of Formula I with an equimolar amount of a strong mineral acid in a solvent for the reactants at a temperature of 0 to 500C. Solvents preferred are lower alkanols such as methanol, ethanol, isopropanol. The salt is precipitated from the alcoholic solution, filtered, washed with a minimal amount of cold alcohol and air dried. Another group of compounds of the present invention which are useful as radiation sensitizers are di(alkylamino) derivatives of chloronitropyrazine. A preferred group of such compounds are represented by the following structural formula: EMI7.1 wherein A is an amino substituent having at least one of the hydrogens of the amino group replaced by a lower alkyl group, an hydroxy lower alkyl group, a polyhydroxy lower alkyl group, a lower alkoxy lower alkyl group or a polyalkoxy lower alkyl group. A preferred sub-group of compounds of the present invention are represented by the following structural formula: EMI7.2 wherein R1 is C16 lower alkyl, C16 branched chain lower alkyl, C1-C6 hydroxyalkyl, C1-C6 polyhydroxyálkyl, C1-C6 alkoxy alkyl or C16 polyalkoxy alkyl R2 is hydrogen or R1 In accordance with our invention the starting compound 5,6-dichloro-3-nitropyrazinamine IV, prepared by heating 3-amino-5,6-dichloropyrazincarboxylic acid with a mixture of fuming sulfuric and fuming nitric acids as described hereinabove is diazotized and exchanged with halogen ion to produce the important novel intermediate 5,6-dichloro-2-halo (C1, Br, I)-3-nitropyrazine VA, which in turn is treated with one or two moles of an alkyl or substituted alkylamine to produce a 2-(alkylamino)3-chloro-6-halo-5-nitropyrazine VIA or 3-chloro-2,6di(alkylamino)-5-nitropyrazine IA as illustrated in the flow sheet below. FLOW SHEET EMI9.1 wherein A is defined as hereinabove and X is halogen selected from chloro, bromo or iodo. As shown in the flow sheet, intermediate VIA is isolated and reacted if desired, with a different species of alkylamine to produce a 2,6-disubstituted-3-chloro-5-nitropyrazine in which the 2 and 6 substituents may differ from each other. In carrying out the first step of our process, starting material IVA is diazotized and exchanged with halogen ion, e.g. chlorine, bromine, or iodine to produce the desired 2-halo-5,6-dichloro3-nitropyrazine VA. In the preferred instance, compound IVA 5,6-dichloro-3-nitropyrazinamine is dissolved in bromoform and to the solution is added at least one mole of an alkyl nitrite compound such as isoamyl nitrite, butyl nitrite, ethyl nitrite and the like. The nitrite reagent is preferably added in approximately an 50-200% molar excess and the reaction mixture is heated at a temperature of 50-120 for a period of 5-40 hours until the reaction is essentially complete as determined by thin layer chromatography. Following the completion of the reaction the desired product is isolated from the cooled reaction mixture by first evaporation of the excess bromoform solvent in vacuo leaving the crude product as a residual oil which is further purified by chromatography over silica gel. In further process steps of the present invention, the intermediate VA condensed with one or two moles of an alkylamine optionally substituted with one or more hydroxy or alkoxy groups to produce the desired product IA in one or more reaction steps with intermediate production, if desired, of the monosubstituted pyrazine VIA hereinabove. This reaction which results in the replacement of the 2 & BR< 6 halogen substitutents by alkylamino substituents is conducted by mixing together 2-halo-5,6-dichloro-3nitropyrazine with at least a 100% molar excess of the selected amine compound and maintaining the reaction temperature at 0-500 for a period of from 0.5 to 16 hours. Preferably the reaction is conducted in the presence of a solvent for the reactants. Suitably, lower aliphatic alcohols such as methanol, ethanol, isopropanol; certain ethers such as tetrahydrofuran; dimethyl formamide, and acetonitrile are useful as solvents for the reaction. Progress of the reaction is conveniently followed by monitoring the disappearance of starting material and appearance of product using thin layer chromatography. Following completion of the reaction the solvent is removed by evaporation in vacuo leaving product as a residual oil which is further purified by trituration with solvents such as ethanol/chloroform mixtures followed by chromatography on silica gel. The products produced of formula IA may be varied by varying the amine reagent. Thus for example, reaction of 2-bromo-5,6-dichloronitropyrazine with one or two moles of selected amine reagent produces the corresponding nitropyrazine in which the 6-chloro and/or the 2-bromo substituent are exchanged by an amino substituent. Another group of compositions of the present invention which are useful as radiation sensitizers are acylated derivatives of 6-(alkylamino)-5chloro-3-nitropyrazinamines in combination with a pharmaceutical carrier. A preferred group of such compounds is represented by the following structural formula: EMI11.1 wherein R and R1 are each hydrogen, C1-C6 loweralkyl and substituted lower alkyl having one or more amino C16 loweralkylamino or dialkylamino, lower alkoxy, hydroxy or halo, including fluoro, chloro or bromo, C1-C6 lower alkyl, and substituted lower alkenyl having one or more amino, C1-C6 alkylamino or dialkylamino, lower alkoxy, or hydroxy groups or when taken together and linked through an additional nitrogen or oxygen constitute a 5-7 member saturated heterocyclic ring comprising a morpholine, a piperazine or an N-substituted piperazine wherein the N-substituent is either hydrogen, C1-C6 alkyl, C1-C6 hydroxyalkyl, C1-C6 alkoxyalkyl; and R2 is a lower alkyl substituent; and a pharmaceutical carrier. One preferred subgroup of active compounds is represented by the formula: EMI12.1 wherein R is haloloweralkyl (fluoro, chloro or bromoalkyl) hydroxy loweralkyl and polyhydroxyloweralkyl of from 1-6 carbons, and R1 is either hydrogen or is defined the same as R and R2 is lower alkyl. In accordance with the present invention the acylaminopyrazines described hereinabove are prepared by acylation and alkylation of the corresponding 5,6dichloro-3-nitropyrazinamine preparation of which is described hereinabove. The 5,6-dichloro-3-nitropyrazinamine is acylated by treatment with an acid halide or an acid anhydride of a loweraliphatic carboxylic acid. Preferably, the 5,6-dichloro-3-nitropyrazinamine is treated at room temperature with a large excess of an acid halide as for example, acetylchloride, acetyl bromide, propionyl chloride, butyryl chloride and the like in the presence of a base such as sodium bicarbonate. The reaction is preferably conducted by mixing the reactants without added solvent at room temperature and heating the reactants at reflux temperature of the mixture for a period of 5 hours to 4 days to insure maximum yield of product. Following the reaction period the entire mixture is evaporated in vacuo to remove excess acylating agents or alternatively quenched in water and extracted with a solvent for the product. After removal of volatile material by evaporation in vacuo the product remains as a residue and is conveniently further purified by chromatography over silica gel. The 2-acylamino-5,6-dichloro-3-nitropyrazine thus produced is then treated with an amine compound to replace the chloro-substituent as illustrated hereinbelow; EMI14.1 wherein R, R1 and R2 are defined as in Compound IB hereinabove. The reaction of the dichloroacylamino nitropyrazine IIIB with the amine compound is preferably carried out in a solvent for the reactants. The solvent employed is a lower alkanol such as methanol, ethanol or isopropanol; ethers such as tetrahydrofuran; N,N-dialkylamides such as dimethyl formamide; and acetonitrile. The amine or thiol reagent is preferably present in approximately a 5-10% molar excess over the nitropyrazine. The reagents are first mixed and then preferably heated to a temperature of 20-800C for a period of from 0.5 to 24 hours. In addition to the reagents and the solvent it is generally preferred to carry out the reaction in the presence of at least an equimolar amount of an organic base. Tertiary amines such as triethylamine and pyridine are preferred. The progress of the reaction is followed by the use of thin layer chromatography. Following the reaction the product is recovered after first evaporating volatile solvents and reactants in vacuo leaving the product as a residue. This residue is then dissolved in a water immiscible solvent such as ethylacetate and the resulting extract of product washed with water and evaporation in vacuo to produce substantially pure product. The method of treatment of human patients or domestic animals undergoing radiation treatment of malignant disease processes employs the compounds of the present invention in pharmaceutical compositions that are administered orally or parenterally, preferably intravenously. The dose employed depends on the radiation protocol for each individual patient. In protocols where the radiation dose is divided into a large number of fractions, the drug can be administered at intervals in the schedule and not necessarily with each radiation treatment. In general, the drug is administered from 10 minutes to 5 hours prior to the radiation treatment in a dosage amount of between 0.25 to about 4.0 grams per square meter of body surface. The preferred dosage form for intravenous administration is a sterile isotonic solution of the drug. Oral dosage forms such as tablets, capsules, or elixirs may also be employed. Capsules containing from 100 to 500 mg. of drug/capsule are satisfactory for use in the method of treatment of our invention. The following examples are intended to illustrate but do not limit the process of preparation, product, compositions, or method of treatment aspects of the invention. EXAMPLE 1-1 2[i6-Amino-3-chloro-5-nitroPyrazin-2-yl)aminolethanol STEP A: Preparation of 5,6-dichloro-3-nitro pyrazinamine (11) To 450 ml concentrated sulfuric acid cooled to 100 is added 50.0 g (0.2m) 3-amino-5,6dichloropyrazine carboxylic acid. To this solution cooled to 0-5 , is added a cold solution of 15 ml fuming sulfuric acid in 15 ml fuming nitric acid dropwise over 15 minutes. The reaction mixture is stirred at 0-5 for 2 hours and then at ambient temperature for 2 hours. The reaction mixture is then poured onto ice and the yellow solid is collected. This solid is taken up in ethyl acetate, washed twice with saturated sodium carbonate solution and then the solution is filtered through a pad of silica gel. The resulting solution is evaporated in vacuo to afford 35 g of 5,6-dichloro-3-nitropyrazinamine, m.p. 169-1700C. STEP B: Preparation of 2[(6-Amino-3-chloro-5-nitro- pyrazin-2yl)aminol ethanol To 1.0 g of 5,6-dichloro-3-nitropyrazinamine in 20 ml isopropanol is added 0.5 ml triethylamine and then 0.3 ml 2-aminoethanol. The reaction mixture is stirred for 3 hours and then concentrated in vacuo to solids. The solids are triturated with hot chloroform and recrystallized from acetonitrile to afford 0.6 g of 2[(6-Amino-3-chloro-5-nitropyrazin2-yl)amino]ethanol, m.p. 196-1970C. Employing the procedure substantially as described in Example 1-1, but employing in Step B the appropriate amine, there are produced: Example Reagent Product m.p. 2 diethanolamine 2-[(6-amino-3- 194-1960C chloro-5-nitro pyrazin-2-yl)amino]- di-ethanol 3 2-amino-2- 2-[(6-amino-3- 214-2150C methyl-1,3- chloro-5-nitro propanediol pyrazin-2-yl)amino] 2-methyl-1,3 propanediol 4 3-amino-1,2- 3-[(6-amino-3- 202-2040C propanediol chloro-5-nitro pyrazin-2-yl)amino] 1,2-propanediol 5 morpholine N-(6-amino-3- 211-2120C chloro-5-nitro pyrazin-2-yl) morpholine 6 aniline N-(6-amino-3- 236-2370C chloro-5-nitro pyrazin-2-yl) aniline 7 N-methyl- 2-[(6-amino-3- 166-1670C ethanolamine chloro-5-nitro pyrazin-2-yl) amino] - N-methyl ethanol 8 Ethyl 3-amino- Ethyl 3-[(6-amino- 162-1630C crotonate 3-chloro-5-nitro pyrazin-2-yl) amino] - crotonate 9 4-Methyl 5-Chloro-6-(4- 186-1880C piperazine methyl-l-piperazinyl) 3-nitropyrazine amine 10 2-(dimethylamino) 5-Chloro-6[2- ethyl amine (dimethylamino) ethyl amino]3 nitropyrazine amine EXAMPLE 1-2 2,2'-1(3-chloro-5-nitropyrazin-2,6-yl)diamino]diethanol STEP A: 2-Bromo-5,6-dichloronitropyrazine To 4.8 g isoamylnitrite in 150 ml bromoform heated to 95-100 is added portionwise 5.0 g 5,6-dichloro-3-nitro-pyrazinamine. The reaction mixture is heated at reflux for 18 hours. After cooling, the bromoform is removed in vacuo to give an oil which is chromatographed on silica gel. The initial component to elute is 5,6-dichloro-2-bromonitropyrazine, which is obtained (2.6 g) as a viscous oil. STEP B: Preparation of 2,2'-[(3-chloro-5-nitro pyrazin-2,6-yl) diamino] diethanol To a solution of 1.0 g 2-bromo-5,6-dichloronitropyrazine in 10 ml isopropanol at 0-100 is added 0.72 g triethylamine and then 0.44 g 2-aminoethanol. The reaction mixture is stirred at 0-100 for 0.5 hour and then at room temperature for 0.5 hour. The solvent is then removed in vacuo and the residue triturated with ethanol/chloroform solution to afford a yellow solid which is collected by filtration. This solid is chromatographed on silica gel and the initial compound to elute is 2,2'-[(3-chloro-5-nitropyrazin-2,6-yl)diamino] diethanol, 0.5 g, mp. 148-150 . STEP B1: 2-E(6-Bromo-3-chloro-5-nitropyrazin-2- yl)-amino]ethanol To 1.8 g of 2-bromo-5,6-dichloronitropyrazine in 10 ml isopropanol at 0-100 is added 0.6 g triethylamine and then 0.31 g ethanolamine. The reaction mixture is stirred at 0-10 for 0.5 hour and then at room temperature for 15 minutes. The solvent is then removed in vacuo and the resulting oil chromatographed on silica gel with elution by 2% methanol/chloroform. The desired product is collected as a clear oil, identity confirmed by mass spectral analysis. This oil is treated with 0.31 g of ethanolamine and 0.6 g of triethylamine to form 2,2'-1(3-chloro-5-nitropyrazin-2,6-yl)diaminol¯ methanol. Employing the procedure substantially as described in Example 1-2B but employing in Step B the appropriate reagent, there is produced the product shown: EXAMPLE 2-2 REAGENT PRODUCT 3-amino-1,2-propanediol 3-chloro-2,6-di(2,3-di hydroxypropylamino)-5 nitropyrazine EXAMPLE 3-2 REAGENT PRODUCT Diethylamine 3-chloro-2,6-diethylamino 5-nitropyrazine EXAMPLE 1-3 N-15-chloro-6(2,3-dihydroxypropyl)amino-3-nitropyra- zinyl]acetamide STEP A: Preparation of N-(5,6-dichloro-3-nitro pyrazin-2-yl)acetamide To 1.0 g of 5,6-dichloro-3-nitropyrazinamine in 15 ml acetyl chloride under nitrogen atmosphere at room temperature is added 0.84 g anhydrous sodium bicarbonate. The reaction mixture is then stirred and heated at reflux for 4 days. Excess acetyl chloride is then removed in vacuo and the residue is chromatographed on silica gel. The desired product is eluted from the column with chloroform. STEP B: N- [5-chloro-6(2,3-dihydroxypropyl) amino-3- nitropyrazinyllacetamide To 0.20 g of acetamide in 35 ml isopropanol at room temperature is added 0.8 g triethylamine followed by 0.73 g 3-amino-1,2-propanediol. The reaction mixture is stirred at room temperature for 1 hour. Then, the solvent is removed in vacuo, and the residue taken up in ethyl acetate and washed twice with 10 ml water. The dried ethyl acetate extract is stripped in vacuo to give a yellow solid, which is recrystallized from acetonitrile to give the title conpound, m.p. 130-1310. Employing the procedure substantially as described in Example 1-2, Step B but employing in Step B an equivalent amount of the indicated appropriate amine reagent there is produced. EMI22.1 <tb> Example <SEP> Reagents <SEP> Product <tb> 2-3 <SEP> UIHCDCR,iSv <SEP> J <SEP> 013 <SEP> oH <tb> <SEP> tHCoMHCt)C2R5 <SEP> t <tb> <SEP> ¯ <SEP> I <SEP> I <SEP> cNk <tb> <SEP> 132N <tb> <SEP> 2 <tb> <SEP> N-15-Chloro-6-(2,3 <tb> <SEP> dihydroxypropyl)amino <tb> <SEP> 3-nitropyrazinyl]pro <tb> <SEP> pionamide <tb> 3-3 <tb> <SEP> OH <tb> <SEP> 411Ctl <SEP> t <SEP> C C3X7 <SEP> 2 <SEP> NN <SEP> < <SEP> <tb> <SEP> OH <SEP> t <tb> <SEP> N-[5-Chloro-6(2,3-di <tb> <SEP> hydroxypropyl)amino-3 <tb> <SEP> nitropyrazinyl] <SEP> butyr <tb> <SEP> amide <tb> 4-3 <tb> <SEP> N2N013 <SEP> + <SEP> RWHODCH3 <SEP> ss <tb> <SEP> C1 <SEP> N <SEP> SO2 <tb> <SEP> N-[5-Chloro-6(2-hy <tb> <SEP> droxyethyl)amino-3 <tb> <SEP> nitropyrazinyl]acet <tb> <SEP> amide <tb> EMI23.1 <tb> Example <SEP> Reagents <SEP> Product <tb> 5-3 <tb> <SEP> Cl <tb> <SEP> 1 <SEP> 3 <SEP> + <SEP> m <SEP> CDM <SEP> cos <SEP> o <SEP> ss <SEP> NHCOCH3 <tb> 8 <SEP> p <SEP> Cl <SEP> ND2 <tb> <SEP> N-[5-chloro-6-(4 <tb> <SEP> methyl-l-piperazin <tb> <SEP> yl)-3-nitropyrazin <tb> <SEP> yli <SEP> acetamide <tb> 6-3 <tb> EMI23.2 N-[5-Chloro-6(di- methylaminoethyl)-3nitropyrazinyl]acet- amide EXAMPLE 7-3 Sterile Isotonic Solutions for Injection Suitable formulations for injection are prepared by dissolving each of the compounds of the preceding Examples in isotonic solution in a concentration of about 1 mg/ml and sterilizing the resulting solution. It is suitable for intravenous injection. EXAMPLE 8-3 Capsules Suitable formulations for oral administration are prepared by filling appropriately sized capsules individually with 100 and 500 mg portions of each of the compounds produced in accordance with the preceding Examples.

Claims: WHAT IS CLAIMED IS: 1. A pharmaceutical composition useful in enhancing the therapeutic effect of radiation treatment comprising an effective amount of a radiation enhancing compound of the formula EMI25.1 wherein R and R1 are each C1-C6 loweralkyl and substituted lower alkyl having one or more amino C1-C6 lower alkylamino or dialkylamino, lower alkoxy, hydroxy or halo including fluoro, chloro, or bromo, C1-C6 loweralkenyl, and substituted lower alkenyl having one or more amino, C1-C6 alkylamino or dialkylamino, loweralkoxy, or hydroxy groups or when taken together and linked through an additional nitrogen or oxygen constitutes a 5-7 member saturated heterocyclic ring comprising a morpholine, a piperazine or an N-substituted piperazine wherein the N-substituent is either hydrogen, C1-C6 alkyl, C1-Cs hydroxyalkyl, C1-C6 alkoxyalkyl and a pharmaceutical carrier. 2. A process for the preparation of a compound of formula: EMI26.1 wherein R and R' are defined as in Claim 1 which comprises contacting 5,6-dichloro-3-nitropyrazinamine with an amine of formula: EMI26.2 3. A method of enhancing the therapeutic effect of radiation treatment which comprises administering to a patient in need of such radiation treatment an effective sensitizing amount of a compound having the formula: EMI26.3 wherein R and R' are as defined in Claim 1. 4. A pyrazine compound of the formula EMI27.1 wherein R1 and R2 are each lower alkyl substituted with one or more hydroxy or halogen groups including fluoro, chloro, bromo or lower alkenyl substituted with one or more hydroxy groups. 5. A compound of the formula: EMI27.2 wherein A is defined as an amino substituent having at least one of the hydrogens of the amino groups replaced by a hydroxy substituted lower alkyl or an alkoxy substituted lower alkyl. 6. A compound of the formula: EMI27.3 wherein X is defined as chloro, bromo or iodo. 7. A compound of the formula: EMI28.1 wherein A is defined in Claim 5 and X is halogen including chloro, bromo and iodo. 8. A process for the preparation of a compound having the formula: EMI28.2 wherein A is defined as in Claim 5 which comprises contacting a compound having the formula: EMI28.3 with a compound selected from a hydroxyloweralkylamine or an alkoxyloweralkylamine in the presence of an organic base. 9. A method of enhancing the therapeutic effect of radiation treatment which comprises administering to a patient in need of such radiation treatment an effective sensitizing amount of a compound having the formula EMI29.1 wherein A is defined as in Claim 5. 10. A composition useful in enhancing the therapeutic effect of radiation treatment comprising a compound of the formula. EMI29.2 wherein A is defined as in Claim 5 and a pharmaceutical carrier. 11. A pharmaceutical composition useful in enhancing the therapeutic effect of radiation treatment comprising an effective amount of a radiation enhancing compound of the formula: EMI30.1 wherein R and R1 are each hydrogen, C1-C6 loweralkyl and substituted lower alkyl having one or more amino C16 loweralkylamino or dialkylamino, lower alkoxy, hydroxy or halo, including fluoro, chloro or bromo, C1-C6 lower alkenyl, and substituted lower alkenyl having one or more amino, C1-C6 alkylamino or dialkylamino, lower alkoxy, or hydroxy groups or when taken together and linked through an additional nitrogen or oxygen constitute a 5-7 member saturated heterocyclic ring comprising a morpholine, a piperazine or an N-substituted piperazine wherein the N-substituent is either hydrogen, C1-C6 alkyl, C1-C6 hydroxyalkyl, C1-C6 alkoxyalkyl; and R2is a lower alkyl substituent; and a pharmaceutical carrier. 12. A chloronitropyrazine compound of the formula: EMI30.2 wherein R is hydroxyloweralkyl, polyhydroxyloweralkyl, or haloloweralkyl, and R1 is hydrogen or R1; R is a lower alhl radical. 13 N-[5-chloro-6(2,3dihydroropyl)amino-3- nitropyrazinyl]acetamide. 14 N-[5-chloro-6(2,3-dihydroxgpropyl)amino-3- nitropyrazinyl]butyramide. 15 A process for the preparation of a chloronitropyrazine compound of the formula: EMI31.1 wherein R, R1 and R2 are as defined as in claim 11 which comprises contacting 5,6-dichloro-3-nitropyrazinamine with a halide or anhydride of a lower aliphatic acid to produce an acylated 5,6-dichloro-3-nitropyrazinamine of the formula: EMI32.1 and contacting said acylated nitropyrazinamine with an amine of the formula: EMI32.2 wherein R and R1 are as defined in Claim 11. 16. A method of enhancing the therapeutic effect of radiation treatment which comprises administering to a patient in need of such radiation treatment an effective sensitizing amount of a compound of the formula: EMI32.3 wherein R, RÚ and Rê are defined as in Claim 11. CLAIMS 1. A pharmaceutical composition useful in enhancing the therapeutic effect of radiation treatment comprising an effective amount of a radiation-enhancing compound of the formula: EMI33.1 where each of R and R1 is C16 alkyl, C16 substituted alkyl having one or more amino, C1 6 alkylamino, di(C1 -6 alkyl)amino, C1-6 alkoxy or hydroxy substituents, C2-6 alkenyl, or C26 substituted alkenyl having one or more amino, Cm1-6 alkylamino, di(C16 alkyl)amino, C1-6 alkoxy or hydroxy substituents, or R and R1 together form a morpholine, piperazine or Nsubstituted piperazine ring in which the N-substituent is hydrogen, C 1-6 alkyl, C1-6 hydroxyalkyl or C16 alkoxyalkyl; and a pharmaceutical carrier. 2. A process for the preparation of a compound of formula: EMI33.2 where R and R1 are as defined in Claim 1 which comprises contacting 5,6dichloro-3-nitropyrazinamine with an amine of formula: EMI33.3 3. For use in enhancing the therapeutic effect of radiation treatment, an effective sensitizing amount of a compound having the formula: EMI34.1 where R and R1 are as defined in Claim 1. 4. A process for the preparation of a compound having the formula: EMI34.2 where A is an amino substituent having at least one of the hydrogens of the amino groups replaced by a hydroxy-substituted C16 alkyl or an alkoxysubstituted C16 alkyl which comprises contacting a compound having the formula: EMI34.3 where X is chlorine, bromine or iodine, with a hydroxyloweralkylamine or an alkoxyloweralkylamine in the presence of an organic base. 5. For use in enhancing the therapeutic effect of radiation treatment, an effective sensitizing amount of a compound having the formula: EMI34.4 where A is defined as in Claim 4. 6. A composition useful in enhancing the therapeutic effect of radiation treatment comprising a compound of the formula: EMI35.1 where A is defined as in Claim 4 and a pharmaceutical carrier. 7. A pharmaceutical composition useful in enhancing the therapeutic effect of radiation treatment comprising an effective amount of a radiation enhancing compound of the formula: EMI35.2 where each of R and R1 is hydrogen, C1-6 alkyl, C 6 substituted alkyl having one or more amino, C1-6 alkylamino, di(C1-6 alkyl)amino, C1-6 alkoxy or hydroxy substituents, C2-6 alkenyl, or C26 substituted alkenyl having one or more amino, C16 alkylamino, di(C1-6 alkyl)amino, C¯6 alkoxy or hydroxy substituents, or R and R together form a morpholine, piperazine or N-substituted piperazine ring in which the N-substituent is hydrogen, C1-6 alkyl, C1-6 hydroxyalkyl or C16 alkoxyalkyl; and R2 is C16 alkyl; and a pharmaceutical carrier. 8. A process for the preparation of a chloronitropyrazine compound of the formula: EMI35.3 where R, R1 and R2 are as defined as in Claim 7, which comprises contacting 5,6-dichloro-3-nitropyrazinamine with a halide or anhydride of a lower aliphatic acid to produce an acylated 5,6-dichloro-3-nitropyrazinamine of the formula: EMI36.1 and contacting said acylated nitropyrazinamine with an amine of the formula: EMI36.2 where R and R1 are as defined in Claim 7. 9. For use in enhancing the therapeutic effect of radiation treatment, an effective sensitizing amount of a compound of the formula: EMI36.3 where R, R1 and R2 are defined as in Claim 7.

Inventors: HARTMAN, GEORGE D.
Applicants: MERCK & CO. INC.
Application year: 1982
Main classification: C07D241
IPC codes: C07D241